EndoGastric® Solutions Announces Expanded Medicare Reimbursement for Transoral Incisionless Fundoplication (TIF®) Procedure

Effective alternative for long-term control of acid reflux symptoms will now be available to over 60% of Medicare patients

Friday, February 26, 2021

Medicare beneficiaries in 10 Midwestern and Northeastern states will soon have reimbursed access to the Transoral Incisionless Fundoplication (TIF®) procedure following a decision by Medicare Administrative Contractor (MAC) National Government Services, Inc. (NGS). Effective December 1, 2017, this decision benefits the growing number of gastroesophageal reflux (GERD) patients seeking a clinically proven treatment alternative with long-term symptom control.

Anthony Starpoli, M.D., New York said, “There’s a significant treatment gap between daily oral therapy and traditional anti-reflux surgery.”  Patients with Gerd, Starpoli added, “Patients struggling with severe GERD symptoms need access to safe, proven treatment options that offer lasting relief and avoid PPI dependence and risks of more invasive surgical operations. The TIF procedure fills the gap for a therapeutic alternative in treating GERD.”

The NGS decision will provide Part B coverage to approximately 9.3 million Medicare patients in Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont and Wisconsin. By granting Medicare coverage for the TIF procedure, NGS joins MACs Cahaba GBA, CGS Administration, Novitas and Palmetto, who already provide access to 19.4 million Medicare subscribers across an additional 15 states. With the addition of NGS, the total number of Medicare lives covered for the TIF procedure will be approximately 34.4 million nationwide, representing 62 percent of 55.5 million total Medicare beneficiaries.

To date, the TIF procedure has brought relief to more than 20,000 GERD patients worldwide, providing an effective, incisionless surgical solution for the millions of Americans suffering with persistent acid reflux.

“Long-term positive outcomes continue to affirm the TIF procedure as an effective treatment option for controlling chronic, troublesome GERD symptoms,” says Peter Janu, M.D., Wisconsin. “Expanded coverage of TIF will open up more opportunities for patients who wish to avoid or discontinue long-term PPI use and want a less invasive procedure than traditional surgery.”

EndoGastric Solutions continues to work with other MACs and commercial payers to secure coverage for the TIF procedure and ensure that GERD patients nationwide have access to this innovative, incisionless technology. Physicians assessing potential TIF patients may call (860) 619-4133 to speak with a representative for information about appropriate coding, coverage and payment details.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.